相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Graphene oxide as a carbo-catalyst for the synthesis of tri-substituted 1,3,5-triazines using biguanides and alcohols
Shivkumar R. Chaurasia et al.
CATALYSIS COMMUNICATIONS (2020)
Metal free [4+1] and [5+1] annulation reactions to prepare heterocycles using DMF and its derivatives as one-carbon source
Yiwen Xu et al.
TETRAHEDRON LETTERS (2020)
Design, synthesis, and biological evaluation of new 6,N2-diaryl-1,3,5-triazine-2,4-diamines as anticancer agents selectively targeting triple negative breast cancer cells
Ahmad Junaid et al.
RSC ADVANCES (2020)
6,N2-Diaryl-1,3,5-triazine-2,4-diamines: synthesis, antiproliferative activity and 3D-QSAR modeling
Ahmad Junaid et al.
RSC ADVANCES (2020)
Synthesis and computer-aided analysis of the role of linker for novel ligands of the 5-HT6 serotonin receptor among substituted 1,3,5-triazinylpiperazines
Dorota Lazewska et al.
BIOORGANIC CHEMISTRY (2019)
New One-Pot Synthesis of 1,3,5-Triazines: Three-Component Condensation, Dimroth Rearrangement, and Dehydrogenative Aromatization
Ahmad Junaid et al.
ACS COMBINATORIAL SCIENCE (2019)
Design, Synthesis, and Characterization of Ogerin-Based Positive Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68)
Xufen Yu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Identifying Lysophosphatidic Acid Acyltransferase β (LPAAT-β) as the Target of a Nanomolar Angiogenesis Inhibitor from a Phenotypic Screen Using the Polypharmacology Browser PPB2
Marion Poirier et al.
CHEMMEDCHEM (2019)
MICROWAVE-ASSISTED SYNTHESIS OF 1,3,5-TRIAZINES: EFFICIENT APPROACHES TO THERAPEUTICALLY VALUABLE SCAFFOLD
Ahmad Junaid et al.
HETEROCYCLES (2019)
A one-pot synthesis of N2,6-diaryl-5,6-dihydro-1,3,5-triazine-2,4-diamines and systematic evaluation of their ability to host ethanol in crystals
Ahmad Junaid et al.
RSC ADVANCES (2019)
Review of triazine antiprotozoal drugs used in veterinary medicine
M. L. Stock et al.
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS (2018)
1,3,5-Triazine analogs: A potent anticancer scaffold
Rajeev Kumar et al.
Current Signal Transduction Therapy (2018)
Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia
Eytan M. Stein
FUTURE ONCOLOGY (2018)
Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis
Wataru Kawahata et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Aryl-1,3,5-triazine ligands of histamine H4 receptor attenuate inflammatory and nociceptive response to carrageen, zymosan and lipopolysaccharide
Szczepan Mogilski et al.
INFLAMMATION RESEARCH (2017)
1,3,5-Triazines: A promising scaffold for anticancer drugs development
Stella Cascioferro et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer
Josep Maria del Campo et al.
GYNECOLOGIC ONCOLOGY (2016)
Ruthenium-catalyzed synthesis of tri-substituted 1,3,5-triazines from alcohols and biguanides
Ming Zeng et al.
NEW JOURNAL OF CHEMISTRY (2016)
Triazine as a promising scaffold for its versatile biological behavior
Prinka Singla et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65
Xi-Ping Huang et al.
NATURE (2015)
Discovery of Novel and Orally Bioavailable Inhibitors of PI3 Kinase Based on Indazole Substituted Morpholino-Triazines
Sundeep Dugar et al.
ACS MEDICINAL CHEMISTRY LETTERS (2015)
Crystal structure refinement with SHELXL
George M. Sheldrick
ACTA CRYSTALLOGRAPHICA SECTION C-STRUCTURAL CHEMISTRY (2015)
1,3,5-Triazine-based analogues of purine: From isosteres to privileged scaffolds in medicinal chemistry
Felicia Phei Lin Lim et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Aryl-1,3,5-triazine derivatives as histamine H4 receptor ligands
Dorota Lazewska et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Privileged s-triazines: structure and pharmacological applications
Dhruvin R. Shah et al.
FUTURE MEDICINAL CHEMISTRY (2014)
Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
Carolyn D. Britten et al.
INVESTIGATIONAL NEW DRUGS (2014)
Regioselective synthesis of imidazo[1,2-a][1,3,5]triazines and 3,4-dihydroimidazo[1,2-a][1,3,5]triazines from [1,3,5]triazin-2,4-diamines
Pascal Dao et al.
TETRAHEDRON (2013)
WinGX and ORTEP for Windows: an update
Louis J. Farrugia
JOURNAL OF APPLIED CRYSTALLOGRAPHY (2012)
Structure validation in chemical crystallography
Anthony L. Spek
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2009)
Substituted 3-(4-(1,3,5-triazin-2-yl)-phenyl)-2-aminopropanoic acids as novel tryptophan hydroxylase inhibitors
Haihong Jin et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
A short history of SHELX
George M. Sheldrick
ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES (2008)
Antileukemic activity of lysophosphatidic acid acyltransferase-β inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib
Paul La Rosee et al.
CLINICAL CANCER RESEARCH (2006)
Effect of lysophosphatidic acid acyltransferase-β inhibition in acute leukemia
Michael G. Douvas et al.
LEUKEMIA RESEARCH (2006)
分享论文
